All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Bookmark this article
During the European Society of Hematology (ESH) 2nd How I manage: CAR T therapies and bispecific antibodies for my patients 2023 Congress, the Lymphoma Hub spoke to Catherine Thieblemont, Hôpital Saint-Louis, Paris, FR. We asked, How to choose and prepare patients for chimeric antigen receptor (CAR) T-cell therapy?
How to choose and prepare patients for CAR T-cell therapy?
Firstly, Thieblemont discusses the importance of assessing a patient’s disease characteristics and the dynamic nature of the tumor when selecting patients for CAR T-cell therapy. Then, she mentions T-cell fitness as a factor impacting CAR T-cell use in treatment and highlights this as a key discussion point at congress.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
EHA 2019 | Real-world data from the first French cohort of patients treated with CAR T-cell therapy
Catherine Thieblemont from the Hôpital Saint-Louis, Paris, FR, reports on the first French patients treated with CAR T.
EHA 2019 | AUGMENT study: Post-hoc analysis in MZL
Catherine Thieblemont from the Hôpital Saint-Louis, Paris, FR, shares a post-hoc analysis from AUGMENT study in marginal zone lymphoma (MZL).
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox